News
FDA's ODAC delivers one loss, one win for AstraZeneca
The FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.
News
Axsome breaks new ground in Alzheimer's with Auvelity OK
Axsome's Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's disease to be approved by the FDA.
News
NICE backs UCB drug as first uncontrolled gMG therapy
UCB's Rystiggo can be used by the NHS as a backup treatment for people with the rare autoimmune and neuromuscular disease gMG, says NICE.
News
Norgine gets first EU approval for WHIM syndrome therapy
Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.
Market Access
Health, growth & renewal: ABPI 2026 looks to UK’s future
The Association of the British Pharmaceutical Industry (ABPI)'s flagship annual conference took place on Thursday, 23rd April.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
